Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04LSD
|
||||
| Former ID |
DCL000028
|
||||
| Drug Name |
ABT-239
|
||||
| Synonyms |
4-[2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl]benzonitrile
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Phase 1 | [1], [2] | ||
| Company |
Abbott
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H22N2O
|
||||
| InChI |
InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3/t16-/m1/s1
|
||||
| InChIKey |
KFHYZKCRXNRKRC-MRXNPFEDSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Antagonist | [1], [3], [4] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1218). | ||||
| REF 3 | A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands. Assay Drug Dev Technol. 2008 Jun;6(3):339-49. | ||||
| REF 4 | Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol. 2009 May;157(1):139-49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.